Immatics N.V. (NASDAQ: IMTX ) is developing a cell therapy called Anzu-cel (anzutresgene autoleucel, IMA203) for melanoma and other potential cancers that could bring in hundreds of millions or more annually. The company has already produced some data with Anzu-celScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment a ...

By Christy Santhosh (Reuters) -Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing competition from generic drugs. The deal expands Bristol Myers Squibb's CAR T-cell immunotherapy portfolio with Orbital's lead experimental candidate, OTX-201, which is designed to target autoimmune diseases. This marks the company's first major acquisition of the year, as it shift ...

Key Takeaways Bayer and Kumquat begin a phase I study of KQB548 for KRAS G12D-mutated tumors.The study will assess the safety and early efficacy in pancreatic, colorectal and lung cancers.KQB548 is the lead program from Bayer and Kumquat's exclusive oncology collaborationBayer (BAYRY) , along with San Diego, CA-based, privately held company, Kumquat Biosciences, announced the initiation of a phase I study evaluating their investigational inhibitor, KQB548 (BAY 3771249), which is being developed for treating ...

Key Takeaways BlueRock posted 36-month data showing bemdaneprocel remains well tolerated in Parkinson's patientsF-Dopa imaging suggests that transplanted cells survived and engrafted after immunosuppression ended. High-dose patients saw a 17.9-point MDS-UPDRS motor score drop, showing clinically meaningful progress.Bayer AG’s (BAYRY) wholly owned, independently operated subsidiary BlueRock Therapeutics LP announced positive 36-month data from an early-stage study of bemdaneprocel, an investigational cell th ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best conservative stocks to buy now. On September 23, at the Bernstein Insights: Healthcare Leaders and Disruptors, the company emphasized its leadership in cell therapy. Bristol-Myers Squibb Company (BMY) to Capitalize on Cell Therapy Edge to Pursue CAR-T Treatment Opportunities The remarks come on the company treating 13,000 patients with cell therapy while leveraging extensive clinical data. “As we sit four years later, after treating 13,000 patie ...

Ronen Twito, Kadimastem's Executive Chairman and CEO and Alexander C. Zwyer NLS's CEO & Executive Board Member stated: ""We are grateful to our shareholders for their strong support of the merger. Today's outcome marks a pivotal step in creating NewCelX, a transatlantic biopharma leader†The merger will create: Nasdaq-listed company: Under the symbol "NCEL": Governance and capital structure approvals completed Diversified pipeline: Unites Kadimastem's advanced cell therapy programs (including a Phase 2a AL ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced that its President and Chief Executive Officer, Dr. Jennifer Buell, will deliver a featured plenary address at the 10th Annual CAR-TCR Summit, taking place September 23–26, 2025, in Boston, MA. The CAR-TCR Summit is one of the industry’s most influential gatherings of academic, clinical, and biopharma lead ...

Summary of Bristol-Myers Squibb Company (NYSE:BMY) FY Conference Call - September 23, 2025 Company Overview - **Company**: Bristol-Myers Squibb Company (BMY) - **Focus**: Cell therapy, particularly in hematology and autoimmune diseases Key Points and Arguments Cell Therapy Potential - Bristol-Myers Squibb has been involved in cell therapy for four years, launching the first CAR T in multiple myeloma and the third CD19 CAR T [2][3] - The company has treated 13,000 patients, gaining significant clinical and translational data, which has accelerated its pipeline [3] - Current assets include Orva-cel (GPRC5D) and Breyanzi (CD19), both showing promise for durable remissions with a one-time infusion [4][5] Market Dynamics and Challenges - The healthcare system has limited the uptake of CAR T therapies compared to expectations from a decade ago, with only 2 out of 10 eligible patients currently receiving CAR T [16][17] - Community practices treat 70% of patients, and there is a need for better integration of CAR T therapies into these settings [10][11] - Recent reductions in patient burden and REMS (Risk Evaluation and Mitigation Strategy) requirements are expected to improve access and referrals [10][11] Competitive Landscape - Breyanzi has become the number one CD19 CAR T in the U.S., Germany, Japan, and France, attributed to its best-in-class profile and broad indications for B-cell malignancies [14][15] - The company anticipates growth in outpatient settings due to Breyanzi's safety profile, allowing for home monitoring post-infusion [15][16] Innovation and Future Directions - Bristol-Myers Squibb is exploring both autologous and allogeneic CAR T therapies, with a focus on off-the-shelf solutions for broader patient access [22][23] - The company is excited about the potential of GPRC5D in multiple myeloma, especially for patients who are quad-class exposed [27][28] - The dual-targeting approach aims to address the high unmet need in newly diagnosed multiple myeloma patients [37][38] Regulatory Environment - The FDA's current stance has not changed significantly, and the company expects to replicate promising efficacy and safety profiles in upcoming trials [33][35] Long-term Vision - Bristol-Myers Squibb aims to deliver CAR T therapies to over 100,000 patients, expanding into diseases previously thought untreatable [60][61] - The company is committed to creating an ecosystem that facilitates access to CAR T therapies, particularly in rheumatology [55][58] Additional Important Insights - The potential market for CAR T in autoimmune diseases is significantly larger than in hematology, with a three to five times larger patient population [43][44] - The company is actively working to educate and create partnerships among rheumatologists and hematologists to improve patient access to CAR T therapies [55][56] - The excitement around CAR T therapies is palpable, with patients expressing regret for not receiving treatment sooner [19][46] This summary encapsulates the key discussions and insights from the Bristol-Myers Squibb conference call, highlighting the company's strategic focus on cell therapy and its commitment to addressing patient needs in hematology and autoimmune diseases.

Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblasts and fibroblast-derived materials, holding over 270 patents [1][4] - The company will present updates on its fibroblast-based technologies at the 2025 Cell & Gene Meeting on the Mesa Conference scheduled for October 6-8, 2025 [2] - A clinical trial for diabetic foot ulcers is planned to be initiated in the first quarter of 2026 [2] Company Overview - FibroBiologics is based in Houston and is developing a pipeline of treatments targeting chronic diseases, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [4] - The company represents advancements in cell therapy and tissue regeneration [4] Event Details - The presentation at the 2025 Cell & Gene Meeting on the Mesa will take place on October 7, 2025, at 2:15 p.m. MST in FLW Ballroom F [2]

Core Insights - Bayer has made significant progress in developing two potential therapies for Parkinson's disease (PD) [1] Group 1: Clinical Trials - The first participant has been randomized in the pivotal Phase III clinical trial, exPDite-2, for bemdaneprocel, which is an investigational cell therapy for PD [1] - The first European participants have been randomized in the Phase II clinical trial, REGENERATE-PD, for AB-1005, an investigational gene therapy [1] - Both therapies are aimed at treating moderate-stage Parkinson's disease [1]